MIRA INFORM REPORT

 

 

Report Date :

16.08.2013

 

IDENTIFICATION DETAILS

 

Name :

MALLINCKRODT CHEMICAL LIMITED    

 

 

Formerly Known As :

MALLINCKRODT SPECIALTY CHEMICALS LIMITED

 

 

Registered Office :

Perth House Millennium Way Chesterfield S41 8nd S43 3rw

 

 

Country :

United Kingdom

 

 

Financials (as on) :

30.09.2011

 

 

Date of Incorporation :

11.08.1987

 

 

Com. Reg. No.:

02154127

 

 

Legal Form :

Private limited with Share Capital

 

 

Line of Business :

Manufactures and distributes products used in diagnostic procedures and in the treatment of pain and related conditions

 

 

No. of Employees :

79

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Unknown

 

 

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

United Kingdom

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

UNITED KINGDOM - ECONOMIC OVERVIEW

 

The UK, a leading trading power and financial center, is the second largest economy in Europe after Germany. Over the past two decades, the government has greatly reduced public ownership and contained the growth of social welfare programs. Agriculture is intensive, highly mechanized, and efficient by European standards, producing about 60% of food needs with less than 2% of the labor force. The UK has large coal, natural gas, and oil resources, but its oil and natural gas reserves are declining and the UK became a net importer of energy in 2005. Services, particularly banking, insurance, and business services, account by far for the largest proportion of GDP while industry continues to decline in importance. After emerging from recession in 1992, Britain's economy enjoyed the longest period of expansion on record during which time growth outpaced most of Western Europe. In 2008, however, the global financial crisis hit the economy particularly hard, due to the importance of its financial sector. Sharply declining home prices, high consumer debt, and the global economic slowdown compounded Britain's economic problems, pushing the economy into recession in the latter half of 2008 and prompting the then BROWN (Labour) government to implement a number of measures to stimulate the economy and stabilize the financial markets; these include nationalizing parts of the banking system, temporarily cutting taxes, suspending public sector borrowing rules, and moving forward public spending on capital projects. Facing burgeoning public deficits and debt levels, in 2010 the CAMERON-led coalition government (between Conservatives and Liberal Democrats) initiated a five-year austerity program, which aimed to lower London's budget deficit from over 10% of GDP in 2010 to nearly 1% by 2015. In November 2011, Chancellor of the Exchequer George OSBORNE announced additional austerity measures through 2017 because of slower-than-expected economic growth and the impact of the euro-zone debt crisis. The CAMERON government raised the value added tax from 17.5% to 20% in 2011. It has pledged to reduce the corporation tax rate to 21% by 2014. The Bank of England (BoE) implemented an asset purchase program of up to £375 billion (approximately $605 billion) as of December 2012. During times of economic crisis, the BoE coordinates interest rate moves with the European Central Bank, but Britain remains outside the European Economic and Monetary Union (EMU). In 2012, weak consumer spending and subdued business investment weighed on the economy. GDP fell 0.1%, and the budget deficit remained stubbornly high at 7.7% of GDP. Public debt continued to increase.

 

Source : CIA

 


Company identification

 

MALLINCKRODT CHEMICAL LIMITED  

 

Address                                    PERTH HOUSE MILLENNIUM WAY        

CHESTERFIELD           

S41 8ND                                        

S43 3RW                                       

United Kingdom

Telephone                                 +44 012 4656 1200

                   

Company Number:              02154127

Foundation:                               11/08/1987       

Status:                                      Financial Statements too old

VAT Number:                             GB 509491825

 

 

Basic information

 

Legal form                               Private limited with Share Capital

Foundation                              11/08/1987

Company No.                                       02154127

 

 

Previous Names

 

Date of Change                        Previous Name

01/07/1994                                MALLINCKRODT SPECIALTY CHEMICALS LIMITED

30/10/1992                                MALLINCKRODT SPECIALTY CHEMICALS (U.K.) LIMITED

14/07/1989                                FRIES & FRIES LIMITED

 

 

Shareholders

 

Name

Currency

Number of shares

Share type

Nominal value

MALLINCKRODT CHEMICAL HOLDINGS (UK) LTD

GBP

11,933,134

ORDINARY

1

Total Share Capital

 

 

 

GBP 11,933,134

 

 

 

 

 

 

 

 

 

 

 

 

 

Management

 

Directors

Name

Address:

Date of birth

Nationality

Appointment date

Mr Alan Cotton

Mr Dean Leslie Erdal

3 Hazlehurst, Hasland, Chesterfield, Derbyshire S41 OLD

Perth House Millennium Way, Chesterfield S41 8ND

12/09/1958 02/10/1956

British American

11/01/2005 08/09/2013

 

Company Secretary

Name

Address:

Appointment date

TMF CORPORATE ADMINISTRATION SERVICES LIMITED

5th Floor, 6 St Andrew Street, London EC4A 3AE

06/04/2015

 

 

Other Known Addresses

 

Perth House Millennium Way, Hall Lane, Staveley, Chesterfield, Derbyshire S43 3RW

 

 

Company relationships

 

Company No.

 

Status

Country

Ultimate parent

 

 

 

 

lb4bbdBt>

UUVIUIbN MUbLIU LI Ml I bU UUIVIrAN Y

Active

Ireland

 

 

 

 

 

-

COVIDIEN HOLDINGS IRELAND LIMITED

Other

Ireland

-

COVIDIEN FINANCE IRELAND LIMITED

Other

Ireland

-

Covidien Group S.a r.l.

Active

Luxembourg

-

A&E KARNER LIMITED

Non Trading

United Kingdom

-

CDKU.K. LIMITED

Active

United Kingdom

-

COVIDIEN HEALTHCARE HOLDING UK LIMITED

Active

United Kingdom

-

COVIDIEN (UK) COMMERCIAL LIMITED

Active

United Kingdom

-

MALLINCKRODT UK COMMERCIAL LTD

Active

United Kingdom

-

EV3 LIMITED

Active

United Kingdom

-

ARGYLE MEDICAL INDUSTRIES(U.K.)LIMITED

Non Trading

United Kingdom

-

COVIDIEN UK LIMITED

Active

United Kingdom

-

COMFORTA HEALTHCARE LTD

Non Trading

United Kingdom

-

COVIDIEN (UK) MANUFACTURING LIMITED

Non Trading

United Kingdom

-

GANMILL LIMITED

Non Trading

United Kingdom

-

PRYORAND HOWARD (1988) LIMITED

Non Trading

United Kingdom

-

COVIDIEN UK HOLDING LTD

Other

United Kingdom

-

TISSUE SCIENCE LABORATORIES LIMITED

Other

United Kingdom

-

M.S.C.H. INCORPORATED

Active

USA

-

MALLINCKRODT MEDICAL ARGENTINA LIMITED

Other

United Kingdom

-

MALLINCKRODT MEDICAL HOLDINGS (UK) LIMITED

Other

United Kingdom

-

MALLINCKRODT UK LTD

Non Trading

United Kingdom

-

MKG MEDICAL UK LTD

Non Trading

United Kingdom

-

NELLCOR PURITAN BENNETT IRELAND

Other

Ireland

-

COVIDIEN IRELAND COMMERCIAL LIMITED

Active

Ireland

-

MALLINCKRODT INTERNATIONAL FINANCIAL SERVICES COMPANY

Active

Ireland

-

MALLINCKRODT MEDICAL IMAGING -IRELAND

Other

Ireland

-

COVIDIEN IRELAND LIMITED

Active

Ireland

-

COVIDIEN SERVICES EUROPE LIMITED

Active

Ireland

-

AUTO SUTURE U.K. LIMITED

Non Trading

United Kingdom

-

INBRAND HOLDINGS LIMITED

Non Trading

United Kingdom

-

ADVANCED ABSORBENT PRODUCTS HOLDINGS LIMITED

Non Trading

United Kingdom

-

INBRAND LIMITED

Non Trading

United Kingdom

-

INBRAND UK LIMITED

Non Trading

United Kingdom

Immediate parent

 

 

 

 

 

 

 

 

02678467                      MALLINCKRODT CHEMICAL HOLDINGS (U.K.) Non Trading United Kingdom LIMITED

 

Business activities

 

Main activity

Manufactures and distributes products used in diagnostic procedures and in the treatment of pain and related conditions

 

 

Economic data

 

Turnover and Employees

 

Date of Accounts                      Turnover                      Employees

25/09/2009                                GBP 71,569,000            79

24/09/2010                                GBP 65,862,000            77        

30/09/2011                                GBP 72,593,000            79

Supplementary data

 

Banks

 

Bank Name

Bank Branch Sort Code

BARCLAYS BANK PLC

20-53-30

 

Auditor

 

Auditor name       DELOITTE LLP

 

Events

 

Company history Date

08/08/2008

New Accounts Filed

02/02/2009

Mr D. Timson has resigned as company secretary

15/02/2009

Annual Returns

12/08/2009

New Accounts Filed

12/08/2009

New Accounts Filed

01/02/2010

Annual Returns

14/04/2010

New Company Secretary Ms R. Dennis appointed

20/07/2010

New Accounts Filed

29/01/2011

Annual Returns

02/02/2011

Mr D.J. Haag has left the board

11/04/2011

New Accounts Filed

28/07/2011

New Board Member R.J. Snell appointed

04/02/2012

Annual Returns

06/08/2012

New Accounts Filed

03/10/2012

Change in Reg.Office

14/11/2012

R.J. Snell has left the board

14/11/2012

Ms R.I. Abbott has resigned as company secretary

14/11/2012

New Company Secretary Mrs J.C. Pascucci appointed

15/11/2012

New Board Member Mr D.L. Erdal appointed

08/02/2013

Annual Returns

08/07/2013

Mrs J.C. Pascucci has resigned as company secretary

08/07/2013

New Company Secretary TMF CORPORATE ADMINISTRATION SERVIC appointed

 

 

County Court Judgments (CCJs)

 

There are no County Court Judgments listed against this company

 

 

Accounts

 

Profit & Loss

 

 

30/09/2011

24/09/2010

25/09/2009

 

53

53

53

 

GBP

GBP

GBP

 

Group: No

Group: No

Group: No

Revenue (Turnover)

72,593,000

65,862,000

71,569,000

Export

58,582,000

53,142,000

61,048,000

Cost of sales

65,037,000

56,385,000

55,989,000

Gross Profit

7,556,000

9,477,000

15,580,000

Operating Costs

71,157,000

61,553,000

63,444,000

Wages And Salaries

2,934,000

2,833,000

3,140,000

Pension Costs

459,000

904,000

538,000

Directors Emoluments

183,000

300,000

300,000

Operating Profit

1,436,000

4,309,000

8,125,000

Depreciation

753,000

812,000

819,000

Amortisation

0

0

0

Financial Expenses

0

0

0

Profit Before Tax

-7,892,000

4,311,000

8,271,000

Tax

4,000

-368,000

-2,377,000

Profit After Tax

-7,888,000

3,943,000

5,894,000

Dividends

0

0

0

Minority Interests

0

0

0

Other Appropriations

0

0

0

Retained Profit

-7,888,000

3,943,000

5,894,000

 

Balance Sheet

 

 

30/09/2011

53

GBP

Group: No

24/09/2010

53

GBP

Group: No

25/09/2009

53

GBP

Group: No

Total Tangible Assets

1,756,000

6,437,000

6,318,000

Total Intangible Assets

0

0

0

Total Other Fixed Assets

0

0

0

Total Fixed Assets

1,756,000

6,437,000

6,318,000

Total Inventories

12,284,000

11,415,000

9,973,000

Trade Receivables

11,353,000

11,001,000

10,195,000

Miscellaneous Receivables

26,843,000

22,772,000

30,970,000

Total Receivables

38,196,000

33,773,000

41,165,000

Cash

0

0

0

Other Current Assets

0

0

0

Total Current Assets

50,480,000

45,188,000

51,138,000

Total Assets

52,236,000

51,625,000

57,456,000

Trade Payables

1,003,000

414,000

1,880,000

Bank Liabilities

23,000

252,000

484,000

Other Loans Or Finance

8,429,000

6,015,000

11,491,000

Miscellaneous Liabilities

3,926,000

3,180,000

5,535,000

Short Term HP Finance Lease Liabilities

0

0

0

Total Current Liabilities

13,381,000

9,861,000

19,390,000

Bank Liabilities Due After 1 Year

0

0

0

Other Loans Or Finance Due After 1 Year

0

0

0

Miscellaneous Liabilities Due After 1 Year

6,492,000

1,513,000

1,891,000

Total Long Term Liabilities

6,492,000

1,513,000

1,891,000

Total Liabilities

19,873,000

11,374,000

21,281,000

Called Up Share Capital

11,933,000

11,933,000

11,933,000

Revenue Reserves

16,430,000

24,318,000

20,242,000

Other Reserves

4,000,000

4,000,000

4,000,000

Total Shareholders Equity

32,363,000

40,251,000

36,175,000

 

Financial Ratios

 

 

30/09/2011

24/09/2010

25/09/2009

Pre Tax Profit Margin

-

10.87

6.55

11.56

Return On Capital Employed

-20.31

10.32

21.72

Return On Total Assets Employed

-15.10

8.35

14.39

Return On Net Assets Employed

-24.38

10.71

22.86

Sales Or Net Working Capital

1.96

1.86

2.25

Stock Turnover Ratio

16.92

17.33

13.93

Debtor Days

58.02

60.79

50.85

Creditor Days

5.12

2.28

9.37

Current Ratio

3.77

4.58

2.64

Liquidity Ratio Or Acid Test

2.85

3.42

2.12

Current Debt Ratio

0.41

0.24

0.53

Gearing

20.13

4.38

6.57

Equity In Percentage

61.96

77.97

62.96

Total Debt Ratio

0.61

0.28

0.58

 

Remarks

No up to date financial details have been filed. The 2011/2012 accounts should have been filed by 30.06.2013. In July 2013 Mallinckrodt the pharmaceuticals business was separated from Covidien Pic group to become an independent group. Remains to be seen how it develops under the new structure. Mallinckrodt employs over 5,500 people globally and has Annual revenues in excess of USD 2 billion

 

Trading Address Confirmed: Perth House Millennium Way, Hall Lane, Staveley, Chesterfield, Derbyshire S43 3RW

Branches: Worldwide


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.61.51

UK Pound

1

Rs.94.98

Euro

1

Rs.81.62

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.